Incivo: second hepatitis C protease inhibitor launched

Incivo (telaprevir) is a new oral preparation licensed in combination with peginterferon alfa and ribavirin for the treatment of hepatitis C in both pretreated and treatment-naive adults.

Telaprevir is taken every 8 hours with food
Telaprevir is taken every 8 hours with food


Telaprevir is a direct inhibitor of NS3 protease, which is required by the hepatitis C virus for replication.1


Telaprevir has been investigated in 2 studies in treatment-naïve patients (ADVANCE and ILLUMINATE) and 1 study in patients previously treated with peginterferon and ribavirin (REALIZE). Patients received telaprevir, in combination with peginterferon alfa and ribavirin, for 8 or 12 weeks followed by 12–24 weeks of peginterferon alfa and ribavirin alone, depending on virological response. In all studies, patients who received telaprevir had a significantly higher rate of sustained virological response at 24 weeks after last planned dose of study drug.2–4


  1. Incivo Summary of Product Characteristics, 2011.
  2. Jacobson IM et al. N Engl J Med 2011; 364(25): 2405-16.
  3. Sherman KE et al. N Engl J Med 2011; 365(11): 1014-24.
  4. Zeuzeum S et al. N Engl J Med 2011; 364(25): 2417-28.

View Incivo drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases